Veeral Desai - Apr 19, 2022 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Strategy & Dev. Officer
Signature
/s/ Lyn Amor Macaraeg, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Apr 19, 2022
Transactions value $
-$4,581,860
Form type
4
Date filed
4/21/2022, 04:05 PM
Previous filing
Sep 29, 2022
Next filing
Apr 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $106K +106K +38.23% $1.00* 385K Apr 19, 2022 Direct F1
transaction AGL Common Stock Sale -$2.42M -106K -27.66% $22.74 278K Apr 19, 2022 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $106K +106K +38.23% $1.00* 385K Apr 20, 2022 Direct F1
transaction AGL Common Stock Sale -$2.38M -106K -27.66% $22.34 278K Apr 20, 2022 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -106K -12.06% $0.00 775K Apr 19, 2022 Common Stock 106K $1.00 Direct F5
transaction AGL Options (Rights to Buy) Options Exercise $0 -106K -13.72% $0.00 669K Apr 20, 2022 Common Stock 106K $1.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.90 to $23.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.76 to $22.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on April 27, 2017 and fully vested on April 27, 2021.